ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

NCI, Canary Foundation Fund Biomarker Studies In Lung Cancer Of Never-Smokers

May 8, 2009

Liver Transplants Extend Survival In Early-Stage Cancer

January 27, 2006

NCI Begins PLCO Screening Trial

November 26, 1993

In Brief: Money Bill Delay Seen Until After Election ACCC Meeting Planned On Community Programs

September 15, 1978

Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista

March 12, 1999

SAIC-Frederick Makes Awards To Proteomics Research Teams.

January 14, 2005